Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant <named-content content-type="genus-species">Acinetobacter baumannii</named-content> Clinical Isolates

ABSTRACT Nosocomial infections with Acinetobacter baumannii are a global problem in intensive care units with high mortality rates. Increasing resistance to first- and second-line antibiotics has forced the use of colistin as last-resort treatment, and increasing development of colistin resistance i...

Full description

Bibliographic Details
Main Authors: Vincent Trebosc, Sarah Gartenmann, Marcus Tötzl, Valentina Lucchini, Birgit Schellhorn, Michel Pieren, Sergio Lociuro, Marc Gitzinger, Marcel Tigges, Dirk Bumann, Christian Kemmer
Format: Article
Language:English
Published: American Society for Microbiology 2019-08-01
Series:mBio
Subjects:
Online Access:https://journals.asm.org/doi/10.1128/mBio.01083-19
_version_ 1818754337266991104
author Vincent Trebosc
Sarah Gartenmann
Marcus Tötzl
Valentina Lucchini
Birgit Schellhorn
Michel Pieren
Sergio Lociuro
Marc Gitzinger
Marcel Tigges
Dirk Bumann
Christian Kemmer
author_facet Vincent Trebosc
Sarah Gartenmann
Marcus Tötzl
Valentina Lucchini
Birgit Schellhorn
Michel Pieren
Sergio Lociuro
Marc Gitzinger
Marcel Tigges
Dirk Bumann
Christian Kemmer
author_sort Vincent Trebosc
collection DOAJ
description ABSTRACT Nosocomial infections with Acinetobacter baumannii are a global problem in intensive care units with high mortality rates. Increasing resistance to first- and second-line antibiotics has forced the use of colistin as last-resort treatment, and increasing development of colistin resistance in A. baumannii has been reported. We evaluated the transcriptional regulator PmrA as potential drug target to restore colistin efficacy in A. baumannii. Deletion of pmrA restored colistin susceptibility in 10 of the 12 extensively drug-resistant A. baumannii clinical isolates studied, indicating the importance of PmrA in the drug resistance phenotype. However, two strains remained highly resistant, indicating that PmrA-mediated overexpression of the phosphoethanolamine (PetN) transferase PmrC is not the exclusive colistin resistance mechanism in A. baumannii. A detailed genetic characterization revealed a new colistin resistance mechanism mediated by genetic integration of the insertion element ISAbaI upstream of the PmrC homolog EptA (93% identity), leading to its overexpression. We found that eptA was ubiquitously present in clinical strains belonging to the international clone 2, and ISAbaI integration upstream of eptA was required to mediate the colistin-resistant phenotype. In addition, we found a duplicated ISAbaI-eptA cassette in one isolate, indicating that this colistin resistance determinant may be embedded in a mobile genetic element. Our data disprove PmrA as a drug target for adjuvant therapy but highlight the importance of PetN transferase-mediated colistin resistance in clinical strains. We suggest that direct targeting of the homologous PetN transferases PmrC/EptA may have the potential to overcome colistin resistance in A. baumannii. IMPORTANCE The discovery of antibiotics revolutionized modern medicine and enabled us to cure previously deadly bacterial infections. However, a progressive increase in antibiotic resistance rates is a major and global threat for our health care system. Colistin represents one of our last-resort antibiotics that is still active against most Gram-negative bacterial pathogens, but increasing resistance is reported worldwide, in particular due to the plasmid-encoded protein MCR-1 present in pathogens such as Escherichia coli and Klebsiella pneumoniae. Here, we showed that colistin resistance in A. baumannii, a top-priority pathogen causing deadly nosocomial infections, is mediated through different avenues that result in increased activity of homologous phosphoethanolamine (PetN) transferases. Considering that MCR-1 is also a PetN transferase, our findings indicate that PetN transferases might be the Achilles heel of superbugs and that direct targeting of them may have the potential to preserve the activity of polymyxin antibiotics.
first_indexed 2024-12-18T05:21:39Z
format Article
id doaj.art-91810f005a4447e3bedcd876f3281f97
institution Directory Open Access Journal
issn 2150-7511
language English
last_indexed 2024-12-18T05:21:39Z
publishDate 2019-08-01
publisher American Society for Microbiology
record_format Article
series mBio
spelling doaj.art-91810f005a4447e3bedcd876f3281f972022-12-21T21:19:38ZengAmerican Society for MicrobiologymBio2150-75112019-08-0110410.1128/mBio.01083-19Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant <named-content content-type="genus-species">Acinetobacter baumannii</named-content> Clinical IsolatesVincent Trebosc0Sarah Gartenmann1Marcus Tötzl2Valentina Lucchini3Birgit Schellhorn4Michel Pieren5Sergio Lociuro6Marc Gitzinger7Marcel Tigges8Dirk Bumann9Christian Kemmer10BioVersys AG, Basel, SwitzerlandBioVersys AG, Basel, SwitzerlandBioVersys AG, Basel, SwitzerlandBioVersys AG, Basel, SwitzerlandBioVersys AG, Basel, SwitzerlandBioVersys AG, Basel, SwitzerlandBioVersys AG, Basel, SwitzerlandBioVersys AG, Basel, SwitzerlandBioVersys AG, Basel, SwitzerlandBiozentrum, University of Basel, Basel, SwitzerlandBioVersys AG, Basel, SwitzerlandABSTRACT Nosocomial infections with Acinetobacter baumannii are a global problem in intensive care units with high mortality rates. Increasing resistance to first- and second-line antibiotics has forced the use of colistin as last-resort treatment, and increasing development of colistin resistance in A. baumannii has been reported. We evaluated the transcriptional regulator PmrA as potential drug target to restore colistin efficacy in A. baumannii. Deletion of pmrA restored colistin susceptibility in 10 of the 12 extensively drug-resistant A. baumannii clinical isolates studied, indicating the importance of PmrA in the drug resistance phenotype. However, two strains remained highly resistant, indicating that PmrA-mediated overexpression of the phosphoethanolamine (PetN) transferase PmrC is not the exclusive colistin resistance mechanism in A. baumannii. A detailed genetic characterization revealed a new colistin resistance mechanism mediated by genetic integration of the insertion element ISAbaI upstream of the PmrC homolog EptA (93% identity), leading to its overexpression. We found that eptA was ubiquitously present in clinical strains belonging to the international clone 2, and ISAbaI integration upstream of eptA was required to mediate the colistin-resistant phenotype. In addition, we found a duplicated ISAbaI-eptA cassette in one isolate, indicating that this colistin resistance determinant may be embedded in a mobile genetic element. Our data disprove PmrA as a drug target for adjuvant therapy but highlight the importance of PetN transferase-mediated colistin resistance in clinical strains. We suggest that direct targeting of the homologous PetN transferases PmrC/EptA may have the potential to overcome colistin resistance in A. baumannii. IMPORTANCE The discovery of antibiotics revolutionized modern medicine and enabled us to cure previously deadly bacterial infections. However, a progressive increase in antibiotic resistance rates is a major and global threat for our health care system. Colistin represents one of our last-resort antibiotics that is still active against most Gram-negative bacterial pathogens, but increasing resistance is reported worldwide, in particular due to the plasmid-encoded protein MCR-1 present in pathogens such as Escherichia coli and Klebsiella pneumoniae. Here, we showed that colistin resistance in A. baumannii, a top-priority pathogen causing deadly nosocomial infections, is mediated through different avenues that result in increased activity of homologous phosphoethanolamine (PetN) transferases. Considering that MCR-1 is also a PetN transferase, our findings indicate that PetN transferases might be the Achilles heel of superbugs and that direct targeting of them may have the potential to preserve the activity of polymyxin antibiotics.https://journals.asm.org/doi/10.1128/mBio.01083-19Acinetobacter baumanniiantibiotic resistancecolistineptAethanolamine transferasemcr-1
spellingShingle Vincent Trebosc
Sarah Gartenmann
Marcus Tötzl
Valentina Lucchini
Birgit Schellhorn
Michel Pieren
Sergio Lociuro
Marc Gitzinger
Marcel Tigges
Dirk Bumann
Christian Kemmer
Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant <named-content content-type="genus-species">Acinetobacter baumannii</named-content> Clinical Isolates
mBio
Acinetobacter baumannii
antibiotic resistance
colistin
eptA
ethanolamine transferase
mcr-1
title Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant <named-content content-type="genus-species">Acinetobacter baumannii</named-content> Clinical Isolates
title_full Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant <named-content content-type="genus-species">Acinetobacter baumannii</named-content> Clinical Isolates
title_fullStr Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant <named-content content-type="genus-species">Acinetobacter baumannii</named-content> Clinical Isolates
title_full_unstemmed Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant <named-content content-type="genus-species">Acinetobacter baumannii</named-content> Clinical Isolates
title_short Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant <named-content content-type="genus-species">Acinetobacter baumannii</named-content> Clinical Isolates
title_sort dissecting colistin resistance mechanisms in extensively drug resistant named content content type genus species acinetobacter baumannii named content clinical isolates
topic Acinetobacter baumannii
antibiotic resistance
colistin
eptA
ethanolamine transferase
mcr-1
url https://journals.asm.org/doi/10.1128/mBio.01083-19
work_keys_str_mv AT vincenttrebosc dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates
AT sarahgartenmann dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates
AT marcustotzl dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates
AT valentinalucchini dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates
AT birgitschellhorn dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates
AT michelpieren dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates
AT sergiolociuro dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates
AT marcgitzinger dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates
AT marceltigges dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates
AT dirkbumann dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates
AT christiankemmer dissectingcolistinresistancemechanismsinextensivelydrugresistantnamedcontentcontenttypegenusspeciesacinetobacterbaumanniinamedcontentclinicalisolates